i. Plasma that is collected by apheresis from individuals who have recovered from COVID-19.
ii. Convalescent plasma that contains antibodies to the SARS-CoV-2.
iii. Is an IND.
iv. As of 8/23/20, the EUA issued by FDA has made CCP available for use in hospitalized patients meeting specific criteria and under conditions without enrollment in a Clinical Trial, EAP, or eIND.
v. The EUA was the result of FDA's conclusion that the "known and potential benefits of COVID-19 convalescent plasma outweigh the known and potential risks of the drug for the treatment of patients hospitalized with COVID-19".